External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
JAMA Netw Open. 2022;5(1):e2144170. doi:10.1001/jamanetworkopen.2021.44170 - January 19, 2022
How does a previously prospectively derived clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy perform prognostically in an external validation cohort?
Read full article>>
Other news & events
- News04.12.2025

#BlueNovemberWithRadiotheranostics for Urologists, Oncologists and Nuclear Medicine physicians
Read more - News10.11.2025

#BlueNovemberWithRadiotheranostics - The VISION trial: Meet Dr Alison Armour
Read more - News06.11.2025

Oncidium Foundation USA Achieves 501(c)(3) Status to Expand Patient Access to Nuclear Medicine and Theranostics
Read more




